Authors

No-Shave November: The Benefits of the Transperineal Versus Transrectal Approach to Prostate Cancer Biopsy

Matthew J. Allaway, DO, discusses the need for a safe, precise and efficient option for performing prostate cancer biopsies via the transperineal approach and the limitations with the current standard of care, which is the transrectal approach, during No-Shave November awareness month.

AI Writes Appeal Letters for Denied Claims...and Wins

Waystar's AI-powered AltitudeAI automates claim appeals, aiming to recover billions in denied payments and reduce healthcare administrative waste.

Naxitamab With GM-CSF Efficacious in Chemo-Resistant High-Risk Neuroblastoma

Naxitamab combined with GM-CSF shows promising results in treating high-risk neuroblastoma, achieving high response rates and manageable safety profiles.

Novel Therapies in Development for Myelofibrosis Show Promise

Srdan Verstovsek, MD, PhD, highlighted recent advancements in developing novel therapeutic strategies for myelofibrosis during SOHO 2022.

The Journey to Holistic Care for Childhood Cancer Patients

As oncologists and the healthcare industry advance their practices to propel care for children, it is crucial for the industry and population at large to tailor care for the unique needs of children to maximize recovery and truly help patients thrive.

From Paper to Pixel: The Power of Digital Referral Systems

By expediting referral processes, enhancing information quality, and boosting patient satisfaction, these systems are reshaping healthcare experiences for both providers and patients.

How AI Is Revolutionizing Oncology in Diagnosis, Treatment, and Research

In this episode of Targeted Talks, Douglas Flora, MD, LSSBB, FACCC, discusses the transformative impact of artificial intelligence in oncology.

Can Just-in-Time Clinical Trials Reduce Disparities in Participation?

Just-in-time trials are 1 tool capable of rapidly increasing access to clinical trials to develop drugs that treat the diverse and unique tapestry of patients across the United States, especially patients with more diverse racial, ethnic, and socioeconomic backgrounds.

Addressing Special Challenges in Older Patients With Hodgkin Lymphoma

CIRT Causes Temporary Urinary Decline, With Recovery by 3 Months

CIRT led to a short-term drop in urinary function in prostate cancer patients, with recovery starting at 3 months and continuing for 5 years.

Mechanism-Driven Science Informs Novel Treatments in Soft Tissue Sarcoma

Various combination strategies are being explored in soft tissue sarcomas in efforts to increase efficacy.

Behind the FDA’s Elimination of REMS Program for CAR T-Cell Therapies

In an interview with Targeted Oncology, Frederick L. Locke, MD, discussed how the elimination of the REMS program for CAR T-cell therapy came about and what effects he hopes this will have on patient access.

World Lymphoma Awareness Day: More Drugs, Targets, and Hope in Non-Hodgkin Lymphoma

Lee Greenberger, PhD, evaluates novel immunotherapies in non-Hodgkin lymphoma for World Lymphoma Awareness Day.

AFM13 Plus AB-101 to Be Tested in Phase 2 Study

The ongoing LuminICE phase 2 study demonstrated that AFM13 in combination with AB-101 may hold promise for the treatment of patients with relapsed or refractory CD30-positive lymphomas.

Lung Cancer Screening Shown to Significantly Boost 20-Year Survival Rate in Patients

In an early-intervention lung screening program, patients with lung cancer were found to have a survival rate nearly 20-times longer than patients with a late-stage diagnosis.

Improved Safety Measures Mark Newest Treatments in Soft Tissue Sarcoma

In early 2020, the treatment paradigm of soft tissue sarcoma had 3 notable advancements with the FDA approving therapies in epithelioid sarcoma, Kaposi sarcoma, and gastrointestinal stromal tumors.

Overall Survival Improved With 177 Lu-Dotatate for Patients With Progressive Midgut NETs

Final overall survival and long-term safety results of the phase 3 NETTER-1 trial were presented during the World Congress on Gastrointestinal Cancer 2021.

Detecting and Addressing Hard-to-Find Skin Cancers

Niraj H. Mehta, MD, reviews the areas of the body where skin cancer can be hard to detect, what the skin cancer will look like on those parts of the body, risk factors for those receiving treatment, and follow-up for patients to catch recurrences.

Expanding Allogeneic Stem Cell Transplantation for Relapsed and Refractory Acute Myeloid Leukemia

Allogeneic HCT has shown promise as definitive treatment for patients with relapsed or refractory AML.

Darolutamide/ADT Safe, Effective for Black Men with Metastatic Prostate Cancer

An ARANOTE substudy showed darolutamide plus ADT significantly improved outcomes (rPFS HR 0.51) and PSA suppression in Black men with mHSPC, with similar safety to overall trial.

How Data Help Physicians Improve Operations and Achieve Health Equity

A US health care executive survey found 30% see health equity solely as a social concern. Yet, it's about ensuring everyone has a fair shot at optimal health. Utilizing standardized data can shift care from reactive to preventive, easing strain on systems.

Glioblastoma Treatment Is Slow to Change, but New Strategies Are Under Investigation

During the past 4 decades, glioblastoma has remained a cancer with one of the worst prognoses and is among the most debilitating.

Steady Progress of AI Makes its Mark in the Clinic

Increasingly, and with exponential pace, AI algorithms are finding their way into the oncology clinic.

Cognitive Behavioral Therapy Improves Dyspnea, Trial Shows

A recent study reveals cognitive behavioral therapy significantly enhances lung cancer patients' ability to manage dyspnea and anxiety, improving overall quality of life.

Trial Results Show Patients With RET Alterations Experience Different Efficacy With Lung Cancer Therapies

During a Targeted Oncology Case-Based Peer Perspectives event, Todd Bauer, MD, medical oncologist, Tennessee Oncology, discussed the results from clinical trials that include patients with RET-altered lung cancer to determine a treatment strategy for a 59-year-old patient.